Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024

The use of sodium glucose cotransporter-2 (SGLT2) inhibitors nearly halves the risk of all-cause mortality at 3 years in patients with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) and type 2 diabetes (T2D), findings from an observational study suggest.

A retrospective analysis presented at HSFA ASM 2024 shows that respiratory syncytial virus (RSV) infection in individuals with heart failure (HF) is associated with greater adverse clinical outcomes.

Patients with obstructive hypertrophic cardiomyopathy (oHCM) can derive broad clinical benefits from treatment with aficamten, which include complete haemodynamic response and improved exercise capacity among others, as shown by the results of the SEQUOIA-HCM study.